Since hepatic Hnf4α is repressed in NASH, the treatment with GT and RT can increase its liver expression, which could be useful in the prevention and progression of NAFLD (46). The gene discussed is HNF4A; the disease is metabolic dysfunction-associated steatotic liver disease.